Chinese Society of Clinical Oncology
China's clinical oncology society, whose annual meeting and disease guidelines are the reference for treatment in the world's largest cancer patient population.
Founded in 1997, CSCO is China's national society of clinical oncologists with tens of thousands of members and a large annual meeting each September that presents Chinese trial data on PD-1 antibodies, antibody-drug conjugates and targeted therapies. Its CSCO guidelines, published annually for each major cancer, grade recommendations by evidence and by accessibility in China and are the guidelines most Chinese oncologists use; they are increasingly cited internationally as Chinese drugs reach global markets. CSCO runs the CSCO Foundation for research grants, expert committees by disease, and a young oncologists' programme, and it holds joint sessions with ASCO, ESMO and JSMO. Its leadership includes the heads of the major Chinese cancer centres.
- CSCO Annual Meeting
- CSCO clinical guidelines (annual, by cancer)
- CSCO Foundation research grants
- Expert committees and international collaboration
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.